HRP20211932T1 - Humana antitijela na fel d1 i postupci njihove upotrebe - Google Patents
Humana antitijela na fel d1 i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20211932T1 HRP20211932T1 HRP20211932TT HRP20211932T HRP20211932T1 HR P20211932 T1 HRP20211932 T1 HR P20211932T1 HR P20211932T T HRP20211932T T HR P20211932TT HR P20211932 T HRP20211932 T HR P20211932T HR P20211932 T1 HRP20211932 T1 HR P20211932T1
- Authority
- HR
- Croatia
- Prior art keywords
- fel
- cat
- antigen
- human monoclonal
- isolated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- 239000012634 fragment Substances 0.000 claims 27
- 241000282326 Felis catus Species 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 7
- 208000030961 allergic reaction Diseases 0.000 claims 7
- 230000035945 sensitivity Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (10)
1. Izolirano humano monoklonsko antitijelo ili njegov fragment koji vezuje antigen koji se specifično veže za alergen mačke Fel d1, gdje:
antitijelo ili fragment koji veže antigen sadrži: (i) HCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 306; i (ii) LCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 314;
i gdje antitijelo ili fragment koji veže antigen je izotip drugačiji od IgA izotipa.
2. Izolirano humano monoklonsko antitijelo ili njegov fragment koji vezuje antigen prema patentnom zahtjevu 1 koje ima izotip koji je izabran iz grupe koja se sastoji iz IgG1, IgG2 i IgG4.
3. Farmaceutski sastav koji sadrži terapeutski efikasnu količinu jednog ili više od izoliranih humanih monoklonskih antitijela, ili njihovih fragmenata koji vezuju antigen, prema patentnom zahtjevu 1 ili 2, koje specifično vezuje Fel d1, zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
4. Farmaceutski sastav prema patentnom zahtjevu 3, koji dalje sadrži drugo izolirano humano monoklonsko antitijelo, ili njegov fragment koji vezuje antigen koji se specifično vezuje za Fel d1.
5. Farmaceutski sastav prema patentnom zahtjevu 4, gdje
(i) izolirano drugo humano monoklonsko antitijelo, ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26, 66/74, 130/138, 162/170, 322/330 i 370/378;
(ii) izolirano drugo humano monoklonsko antitijelo, ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26 i 322/330;
(iii) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 66/74;
(iv) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 130/138;
(v) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 322/330;
(vi) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26; ili
(vii) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 370/378.
6. Farmaceutski sastav prema patentnom zahtjevu 4, koja sadrži dva ili više izolirana humana monoklonska antitijela koja se specifično vežu za Fel d1, ili njihove fragmente koji vezuju antigen, pri čemu izolirano drugo humano antitijelo ili njegov fragment koji vezuje antigen koji se veže specifično za Fel d1 sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26, 66/74, 130/138, i 162/170.
7. Molekula nukleinske kiseline koja kodira humano monoklonsko antitijelo, ili njegov fragment koji se specifično vezuje za Fel d1 prema patentnom zahtjevu 1 ili 2; ekspresijski vektor koji se sastoji iz molekula nukleinske kiseline; ili stanica domaćina koja sadrži ekspresijski vektor.
8. Efikasna količina jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji vezuju antigen koji se specifično vežu za Fel d1, prema patentnom zahtjevu 1 ili 2; ili farmaceutski sastav koji se sastoji iz efikasne količine jednog ili više izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1 prema bilo kojem od patentnih zahtjeva 3-6, za upotrebu u postupku za liječenje:
(a) pacijenta koji iskazuje osjetljivost prema, ili alergijsku reakciju protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu, spomenuti postupak obuhvaća davanje antitijela, njegovog fragmenta, ili farmaceutskog sastava pacijentu kojem je potrebno, gdje osjetljivost prema, ili alergijska reakcija protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu je ili spriječena, ili je smanjena u ozbiljnosti i/ili trajanju, ili da je učestalost i/ili trajanje, ili ozbiljnost osjetljivosti prema ili alergijska reakcija protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu je smanjena nakon davanja jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1, ili nakon davanja sastava koji sadrži bilo koje jedno ili više od navedenih antitijela; ili
(b) bar jedan simptom ili komplikacija koja je povezana s osjetljivošću na, ili alergijskom reakcijom protiv mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu, spomenuti postupak obuhvaća davanje antitijela, njegovog fragmenta, ili farmaceutskog sastava pacijentu kojem je potrebno, gdje bar jedan simptom ili komplikacija koja je povezana s osjetljivošću na, ili alergijskom reakcijom protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu je smanjena, ili ublažena, ili da je učestalost i/ili trajanje, ili ozbiljnost osjetljivosti prema ili alergijska reakcija protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu smanjena nakon davanja jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1, ili nakon davanja sastava koja sadrži bilo koje jedno ili više od navedenih antitijela.
9. Jedno ili više izoliranih humanih monoklonskih antitijela ili njihovi fragmenti koji vezuju antigen, ili farmaceutski sastav koji sadrži efikasnu količinu jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1, za upotrebu prema postupku pod (a) ili (b) prema patentnom zahtjevu 8:
(a) gdje spomenuti postupak dalje obuhvaća davanje efikasne količine drugog terapeutskog sredstva koje je korisno za smanjenje alergijske reakcije na mačku, mačju perut, mačju dlaku ili njezin ekstrakt, ili na Fel d1 protein, opcionalno gdje drugo terapeutsko sredstvo je izabrano iz grupe koja se sastoji iz kortikosteroida, bronhijalnog dilatatora, antihistamina, epinefrina, dekongestanta, drugog različitog antitijela protiv Fel d1 i peptidnog cjepiva; i/ili
(b) gdje tretman rezultira u smanjenju alergijskog rinitisa, alergijskog konjunktivitisa, alergijske astme, ili anafilaktičke reakcije nakon izlaganja pacijenta mački, mačjoj peruti, mačjoj dlaki ili njenom ekstraktu, ili prema Fel d1 proteinu.
10. Farmaceutski sastav prema patentnom zahtjevu 3 koji se sastoji iz dva ili više izolirana humana monoklonska antitijela koja se specifično vežu za Fel d1, ili njihove fragmente koji vezuju antigen, gdje prvo humano antitijelo ili njegov fragment koji se vezuje za antigen sadrži HCVR/LCVR par aminokiselinske sekvence prema SEQ ID NOs: 306/314, i gdje jedan ili više daljih humanih antitijela ili njihovih fragmenata koji vezuju antigen sadrže HCVR/LCVR parove aminokiselinske sekvence koji su izabrani iz grupe koju čine SEQ ID NOs: 18/26, 66/74, 130/138, i 162/170.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US201361783312P | 2013-03-14 | 2013-03-14 | |
| EP19218187.3A EP3660047B1 (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211932T1 true HRP20211932T1 (hr) | 2022-03-18 |
Family
ID=48326501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211932TT HRP20211932T1 (hr) | 2012-05-03 | 2013-05-02 | Humana antitijela na fel d1 i postupci njihove upotrebe |
| HRP20200652TT HRP20200652T1 (hr) | 2012-05-03 | 2020-04-23 | Ljudska antitijela na fel d1 i metode njihove primjene |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200652TT HRP20200652T1 (hr) | 2012-05-03 | 2020-04-23 | Ljudska antitijela na fel d1 i metode njihove primjene |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9079948B2 (hr) |
| EP (3) | EP3978522A3 (hr) |
| JP (2) | JP6400569B2 (hr) |
| KR (1) | KR102185516B1 (hr) |
| CN (2) | CN104411719B (hr) |
| AR (1) | AR090914A1 (hr) |
| AU (2) | AU2013256251C1 (hr) |
| BR (2) | BR112014026852B1 (hr) |
| CA (1) | CA2871077C (hr) |
| CY (2) | CY1124023T1 (hr) |
| DK (1) | DK2844672T3 (hr) |
| ES (2) | ES2898372T3 (hr) |
| HK (1) | HK1202123A1 (hr) |
| HR (2) | HRP20211932T1 (hr) |
| HU (2) | HUE057062T2 (hr) |
| IL (1) | IL235121B (hr) |
| IN (1) | IN2014DN08767A (hr) |
| JO (1) | JO3820B1 (hr) |
| LT (2) | LT2844672T (hr) |
| MX (2) | MX2014013371A (hr) |
| MY (3) | MY195564A (hr) |
| NZ (2) | NZ733480A (hr) |
| PL (2) | PL3660047T3 (hr) |
| PT (2) | PT3660047T (hr) |
| RS (2) | RS62636B1 (hr) |
| RU (1) | RU2658491C2 (hr) |
| SG (3) | SG11201406748QA (hr) |
| SI (2) | SI3660047T1 (hr) |
| TW (2) | TWI644921B (hr) |
| UY (1) | UY34782A (hr) |
| WO (1) | WO2013166236A1 (hr) |
| ZA (3) | ZA201407302B (hr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| JP5813880B2 (ja) | 2011-09-19 | 2015-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| EP3564671B1 (en) * | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| HUE050831T2 (hu) | 2014-11-17 | 2021-01-28 | Regeneron Pharma | Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával |
| AU2016242866B2 (en) | 2015-03-30 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to FC gamma receptors |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| NZ740816A (en) * | 2015-09-08 | 2022-05-27 | Univ Zuerich | Compositions against cat allergy |
| BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018118713A1 (en) * | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| CN110234354B (zh) * | 2017-01-24 | 2023-09-12 | 雀巢产品有限公司 | 包含抗-fel d1抗体的组合物和用于减少人类对猫的过敏症的至少一种症状的方法 |
| KR102659791B1 (ko) | 2017-07-06 | 2024-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| KR20200103728A (ko) | 2017-12-22 | 2020-09-02 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 제품 불순물 특성화를 위한 시스템 및 방법 |
| AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| WO2019168774A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| ES2969882T3 (es) | 2018-03-19 | 2024-05-23 | Regeneron Pharma | Ensayos y reactivos de electroforesis capilar en microchip |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CA3097194A1 (en) | 2018-05-18 | 2019-11-21 | Chan Zuckerberg Biohub, Inc. | Methods of isolating allergen-specific antibodies from humans and uses thereof |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| EA202190032A1 (ru) | 2018-08-30 | 2021-03-12 | Ридженерон Фармасьютикалз, Инк. | Способы определения характеристик белковых комплексов |
| WO2020150491A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| JP2022532503A (ja) | 2019-05-13 | 2022-07-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| EP4034870A1 (en) | 2019-09-24 | 2022-08-03 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| KR20220104797A (ko) | 2019-11-25 | 2022-07-26 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 에멀전을 이용한 지속 방출 제형 |
| WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| US20220064270A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| AU2021332355A1 (en) | 2020-08-31 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| US20220160828A1 (en) | 2020-11-25 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| US20220228107A1 (en) | 2021-01-20 | 2022-07-21 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
| JP2024519407A (ja) | 2021-03-26 | 2024-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 混合プロトコルを作成するための方法およびシステム |
| WO2022256383A1 (en) | 2021-06-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| IL311527A (en) | 2021-09-20 | 2024-05-01 | Regeneron Pharma | Methods for controlling antibody heterogeneity |
| CN118076885A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH计校准与校正 |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN114113278A (zh) * | 2021-11-24 | 2022-03-01 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
| US20230416349A1 (en) | 2022-06-23 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| CN117964767A (zh) * | 2024-03-29 | 2024-05-03 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0621780A1 (en) * | 1992-01-21 | 1994-11-02 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| JPH08501799A (ja) | 1992-12-21 | 1996-02-27 | タノックス バイオシステムズ インコーポレイテッド | アレルゲン特異的ＩｇＡモノクローナル抗体及びアレルギー治療のための関連物質 |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7767212B2 (en) * | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) * | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| NZ614857A (en) | 2007-03-29 | 2015-04-24 | Genmab As | Bispecific antibodies and methods for production thereof |
| US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| PL2705846T3 (pl) | 2007-07-09 | 2017-11-30 | Nestec S.A. | Sposoby zmniejszania alergii wywołanych przez alergeny środowiskowe |
| EP2572729A3 (en) * | 2007-08-10 | 2013-06-05 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 MX MX2014013371A patent/MX2014013371A/es active IP Right Grant
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 EP EP21194412.9A patent/EP3978522A3/en active Pending
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en active Application Filing
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active IP Right Grant
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-03-13 HK HK15102575.2A patent/HK1202123A1/xx unknown
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-04-23 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US20220025029A1/en active Pending
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200652T1 (hr) | Ljudska antitijela na fel d1 i metode njihove primjene | |
| JP2015523962A5 (hr) | ||
| HRP20200846T1 (hr) | Anti-il-33 antitijela i njihove primjene | |
| ES2900342T3 (es) | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R | |
| TWI755763B (zh) | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 | |
| Hoffman | Therapy of autoinflammatory syndromes | |
| CN105517570B (zh) | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 | |
| TW200808821A (en) | Antibody purification | |
| RU2749512C2 (ru) | Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента | |
| HRP20140661T1 (hr) | Apoptotiäśka protutijela anti-ige koja vežu ige spojen s membranom | |
| JP2015534548A (ja) | Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法 | |
| TW200412998A (en) | Treatment of TNF α related disorders | |
| RU2668802C2 (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US11066462B2 (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
| JP2022543815A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 | |
| JP7162097B2 (ja) | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 | |
| EP3564671B1 (en) | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) | |
| CA3173173A1 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| JP2021112207A5 (hr) | ||
| Dimov et al. | Immunomodulators for asthma | |
| Wechsler et al. | Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines | |
| Albrecht | Turning off the alarm–Targeting alarmins and other epithelial mediators of allergic inflammation with biologics | |
| JP2020523004A5 (hr) | ||
| JP2021520854A (ja) | 黄熱を処置するための方法および組成物 |